Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents
Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark, 9000
- Aalborg Universitetshospital Nord/Reumatologisk Afdelning
-
Aarhus C., Denmark, 8000
- Aarhus Universitetshospital/Reumatologisk Afdelning U
-
Esbjerg, Denmark, 6700
- Sydvestjysk Sygehus / Reumatologisk Afdeling
-
Frederiksberg, Denmark, 2000
- Frederiksberg Hospital / Reumatologisk Afdeling
-
Hellerup, Denmark, 2900
- Gentofte Hospital, Medicinsk afd. C
-
Hillerod, Denmark, 3400
- Hillerod Hospital/Reumatologisk Afdeling
-
Holbaek, Denmark, 4300
- Holbaek Sygehus
-
Kolding, Denmark, 6000
- Reumatologisk afd
-
Odense C, Denmark, 5000
- Odense Universitets Hospital/Reumatologisk Afdeling C
-
Randers NØ, Denmark, 8930
- Regionshospitalet Randers / Reumatologisk Klinik
-
Svendborg, Denmark, 5700
- Svendborg Sygehus / Medicinsk Afdeling M
-
Vejle, Denmark, 7100
- Vejle Sygehus / Medicinsk Afdeling
-
Viborg, Denmark, 8800
- Hospitalsenheden Viborg Reumatologisk Ambulatorium
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject fulfils criteria for Rheumatoid Arthritis (RA) according to ACR or EULAR criteria.
- Subjects who are planned to start treatment with ADA, ETA, CER or IFX
- Subjects taking a minimum weekly dose of 7.5 mg of methotrexate
Exclusion Criteria:
- Patients with compliance problems
- Patients who have difficulties in reading and understanding local language
- Patients with Juvenile Idiopathic Arthritis (JIA)
- Azathioprine or cyclophosphamide treatment within 6 months before entering into the study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Etanercept
|
Study with 4 arms/groups with 36 patients per group.
In total 144 patients.
|
|
adalimumab
|
Study with 4 arms/groups with 36 patients per group.
In total 144 patients.
|
|
infliximab
|
Study with 4 arms/groups with 36 patients per group.
In total 144 patients.
|
|
Certolizumab
|
Study with 4 arms/groups with 36 patients per group.
In total 144 patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Anti-drug Antibodies Formation Levels 6 Months After Initiation of Treatment With Adalimumab, Certolizumab, Etanercept or Infliximab
Time Frame: Month 6
|
Anti-drug antibodies to Adalimumab, Certolizumab, Etanercept and Infliximab were to be measured in serum samples using a validated commercially available cell-based reporter-gene assay.
|
Month 6
|
|
Number of Participants With Presence of Active Drugs in Serum 6 Months After Initiation of Treatment With Adalimumab, Certolizumab, Etanercept or Infliximab
Time Frame: Month 6
|
Presence of active drugs in serum 6 months after treatment with Adalimumab, Certolizumab, Etanercept and Infliximab were to be measured in serum samples using a validated commercially available cell-based reporter-gene assay.
|
Month 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation Between Formation of Antibodies to Adalimumab, Certolizumab, Etanercept or Infliximab 6 Months After Initiation of Treatment and Disease Activity Score 28 (DAS28) 12 Months After Initiation of Treatment
Time Frame: Month 6, 12
|
Association between formation of antibodies to Adalimumab, Certolizumab, Etanercept, Infliximab and DAS28 was to be analyzed using Pearson and Spearman correlations across and within each of the four treatment groups.
DAS28-4 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joint count, C-reactive protein (CRP) in milligram per liter (mg/L) and participant global assessment (PGA) of disease activity (participant rated arthritis activity assessment with total score ranging from 0 [good condition] to 10 [worst condition]; higher score indicates worse condition).
DAS28-4 total score range: 0 (no disease activity) to 9.4 (maximum disease activity), higher score indicates more disease activity.
|
Month 6, 12
|
|
Correlation Between Formation of Antibodies to Adalimumab, Certolizumab, Etanercept or Infliximab 6 Months After Initiation of Treatment and Health Assessment Questionnaire (HAQ) 12 Months After Initiation of Treatment
Time Frame: Month 6, 12
|
Association between formation of antibodies to Adalimumab, Certolizumab, Etanercept, Infliximab and HAQ scores was to be analyzed using Pearson and Spearman correlations across and within each of the four treatment groups.
HAQ was a self-reported, valid assessment of functional disability in rheumatoid arthritis based on ability of participants to perform daily activities.
HAQ total score range: 0 (normal functioning) to 3 (worst functioning), where higher score indicates worse functioning.
|
Month 6, 12
|
|
Correlation Between Formation of Antibodies to Adalimumab, Certolizumab, Etanercept or Infliximab 6 Months After Initiation of Treatment and Cessation of Therapy Between Month 6 and 12 Visits
Time Frame: Month 6, 12
|
Association between formation of antibodies to Adalimumab, Certolizumab, Etanercept and Infliximab and cessation of therapy was to be analyzed.
Cessation of therapy between month 6 and month 12 was the time to withdrawal from study due to either adverse events or lack of effect between the 6 month visit and the 12 month visit.
|
Month 6, 12
|
|
Number of Participants With Anti-drug Antibodies Levels 3 and 12 Months After Initiation of Treatment With Adalimumab, Certolizumab, Etanercept or Infliximab
Time Frame: Month 3, 12
|
Anti-drug antibodies to Adalimumab, Certolizumab, Etanercept and Infliximab were to be measured in serum samples using a validated commercially available cell-based reporter-gene assay.
|
Month 3, 12
|
|
Correlation Between the Formation of Anti-drug Antibodies to Adalimumab, Certolizumab, Etanercept or Infliximab and Concomitant Methotrexate Treatment
Time Frame: Month 12
|
Association between formation of anti-drug antibodies to Adalimumab, Certolizumab, Etanercept and Infliximab and concomitant Methotrexate treatment (weekly dose of 7.5 milligram) was to be analyzed.
|
Month 12
|
|
Disease Activity Score Based on 28-Joints Count (DAS28) After Initiation of Treatment With Adalimumab, Certolizumab, Etanercept or Infliximab at Month 3, 6 and 12
Time Frame: Month 3, 6, 12
|
DAS28-4 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joint count, C-reactive protein (CRP) in milligram per liter (mg/L) and participant global assessment (PGA) of disease activity (participant rated arthritis activity assessment with total score ranging from 0 [good condition] to 10 [worst condition]; higher score indicates worse condition).
DAS28-4 total score range: 0 (no disease activity) to 9.4 (maximum disease activity), higher score indicates more disease activity.
DAS28-4 (CRP) less than or equal to (<=) 3.2 implied low disease activity and greater than (>) 3.2 to 5.1 implied moderate to high disease activity.
|
Month 3, 6, 12
|
|
Health Assessment Questionnaire (HAQ) Score After Initiation of Treatment With Adalimumab, Certolizumab, Etanercept or Infliximab at Baseline, Month 3, 6 and 12
Time Frame: Baseline, Month 3, 6, 12
|
HAQ was a self-reported, valid assessment of functional disability in rheumatoid arthritis based on ability of participants to perform daily activities.
HAQ total score range: 0 (normal functioning) to 3 (worst functioning), where higher score indicates worse functioning.
|
Baseline, Month 3, 6, 12
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B1801347
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.